Diabetes Tsunami? China Eyes More Modern Therapies Under 2025 Plan
Executive Summary
Diabetes poses a triple whammy and is likely to cripple China's health care system in near future. To counter, the Chinese government looks at total disease management, long-acting insulins and GLP-1 products.
You may also be interested in...
AstraZeneca Divests Antidiabetics To 3SBio In New China Growth Plan
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.